Cargando…

DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model

SIMPLE SUMMARY: The role of immunity in the development and progression of epithelial ovarian cancer (EOC) is well established. Poor T-cell infiltration is associated with mortality in EOC patients, and recent evidence has suggested that the enzyme DPP4 plays a role in this process. The aim of our s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Amy L., Moffitt, Laura R., Wilson, Kirsty L., Bilandzic, Maree, Wright, Mark D., Gorrell, Mark D., Oehler, Martin K., Plebanski, Magdalena, Stephens, Andrew N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865851/ https://www.ncbi.nlm.nih.gov/pubmed/33513866 http://dx.doi.org/10.3390/cancers13030487

Ejemplares similares

Hypoxia Regulates DPP4 Expression, Proteolytic Inactivation, and Shedding from Ovarian Cancer Cells
por: Moffitt, Laura R., et al.
Publicado: (2020)

Non-Invasive Fluorescent Monitoring of Ovarian Cancer in an Immunocompetent Mouse Model
por: Wilson, Amy L., et al.
Publicado: (2018)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Therapeutic Targeting of Collective Invasion in Ovarian Cancer
por: Moffitt, Laura, et al.
Publicado: (2019)

Chemoresistance is mediated by ovarian cancer leader cells in vitro
por: Karimnia, Nazanin, et al.
Publicado: (2021)

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
por: Koyani, Chintan N., et al.
Publicado: (2018)

A Novel Predictive Multi-Marker Test for the Pre-Surgical Identification of Ovarian Cancer
por: Stephens, Andrew N., et al.
Publicado: (2023)

Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans
por: Xiao, Changting, et al.
Publicado: (2014)

Immune regeneration in irradiated mice is not impaired by the absence of DPP9 enzymatic activity
por: Gall, Margaret G., et al.
Publicado: (2019)

Montanide, Poly I:C and nanoparticle based vaccines promote differential suppressor and effector cell expansion: a study of induction of CD8 T cells to a minimal Plasmodium berghei epitope
por: Wilson, Kirsty L., et al.
Publicado: (2015)

A Model to Study the Impact of Polymorphism Driven Liver-Stage Immune Evasion by Malaria Parasites, to Help Design Effective Cross-Reactive Vaccines
por: Wilson, Kirsty L., et al.
Publicado: (2016)

Functional Recognition by CD8+ T Cells of Epitopes with Amino Acid Variations Outside Known MHC Anchor or T Cell Receptor Recognition Residues
por: Wilson, Kirsty L., et al.
Publicado: (2020)

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012)

Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells
por: Yoon, Hyunyee, et al.
Publicado: (2021)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

Keratin-14 (KRT14) Positive Leader Cells Mediate Mesothelial Clearance and Invasion by Ovarian Cancer Cells
por: Bilandzic, Maree, et al.
Publicado: (2019)

Concanavalin A potentiates syngeneic response in murine lymphocytes
Publicado: (1976)

Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes
Publicado: (1980)

Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression
por: Gao, Qian, et al.
Publicado: (2018)

Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin
por: Cheng, Sheng-Yao, et al.
Publicado: (2022)

Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma
por: McFarland, Braden C., et al.
Publicado: (2016)

A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2
por: Xi, Cecy R, et al.
Publicado: (2020)

Sitagliptin Is More Effective Than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease
por: Ren, Jing, et al.
Publicado: (2022)

DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma
por: Huang, Jiali Carrie, et al.
Publicado: (2021)

The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms
por: Zeng, Yanmei, et al.
Publicado: (2014)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

Mucoadhesive Particles: A Novel, Prolonged-Release Nanocarrier of Sitagliptin for the Treatment of Diabetics
por: SreeHarsha, Nagaraja, et al.
Publicado: (2019)

DPP8/9 inhibitors activate the CARD8 inflammasome in resting lymphocytes
por: Johnson, Darren C., et al.
Publicado: (2020)

Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model
por: Al-awar, Amin, et al.
Publicado: (2018)

Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
por: Katsuno, Tomoyuki, et al.
Publicado: (2016)

NATURE OF THE STIMULATING CELL IN THE SYNGENEIC AND THE ALLOGENEIC MIXED LYMPHOCYTE REACTION IN MICE
por: von Boehmer, H., et al.
Publicado: (1972)

A Nanoparticle Based Sp17 Peptide Vaccine Exposes New Immuno-Dominant and Species Cross-reactive B Cell Epitopes
por: Xiang, Sue D., et al.
Publicado: (2015)

Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8(+) T Cell Responses
por: Xiang, Sue D., et al.
Publicado: (2018)

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
por: Goldenberg, Ronald, et al.
Publicado: (2017)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Sitagliptin and the Blood-Retina Barrier: Effects on Retinal Endothelial Cells Manifested Only after Prolonged Exposure
por: Jäckle, Anja, et al.
Publicado: (2020)

Secondary induction of cytotoxic T lymphocytes with solubilized syngeneic tumor cell plasma membranes
Publicado: (1978)

Formation of a Unique Population of CD8+ T Lymphocytes after Adoptive Transfer of Syngeneic Splenocytes to Mice with Lymphopenia
por: Silaeva, Yu. Yu., et al.
Publicado: (2021)

Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells
por: Moody, Rhiane, et al.
Publicado: (2020)

DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats
por: Alam, Md. Ashraful, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lv3aejl3g8ef302r6kqsh8585p